New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
September 05, 2024 16:01 ET
|
Vor Biopharma
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with...
Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients
June 28, 2018 08:00 ET
|
Actinium Pharmaceuticals
Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse rate highlighting need for improved consolidation therapies Webcast to be held on July 10, 2018 at 8:00 AM...
Actinium Pharmaceuticals Announces Treatment of First Patient in Novel Combination Trial of Actimab-A Plus CLAG-M
June 13, 2018 08:00 ET
|
Actinium Pharmaceuticals
- Trial supports Actinium’s strategic expansion of its CD33 program into novel combinations that can lead to increased use of bone marrow transplants and expand the addressable patient population for...
Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical Development
April 18, 2018 07:30 ET
|
Actinium Pharmaceuticals
- Dr. Vijay Reddy joins Actinium with over 20 years of bone marrow transplant clinical experience including extensive product development experience at Pharmacyclics, an AbbVie Company, Medimmune and...
Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
March 13, 2018 07:30 ET
|
Actinium Pharmaceuticals
Clinical trial to be conducted by the Medical College of Wisconsin as an investigator initiated trial led by Dr. Sameem Abedin in collaboration with Dr. Ehab Atallah Combination trial expands...
Actinium Pharmaceuticals to Present at 30th Annual ROTH Conference
March 07, 2018 07:30 ET
|
Actinium Pharmaceuticals
NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), announced today that it will be attending and presenting at the 30th...
Actinium Announces Submission of IND For Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
February 12, 2018 16:15 ET
|
Actinium Pharmaceuticals
• Conference call to be held on Tuesday, February 13th, 2018 at 4:30 PM ET to discuss planned Phase 1 clinical trial with Dr. Ehab Atallah • New trial represents expansion of Actinium’s CD33 program...
Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation
February 08, 2018 08:00 ET
|
Actinium Pharmaceuticals
- Mr. Kapur joins Actinium with more than two decades of biopharmaceutical commercial experience at Johnson & Johnson, BAXALTA and Bristol-Myers Squibb - Global leader with deep expertise in...
Actinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients
February 06, 2018 07:30 ET
|
Actinium Pharmaceuticals
- Actimab-A plus CLAG-M further expands Actinium’s CD33 program and addressable patient population of Actimab-A - Combination aligns with Actinium’s focus on improving bone marrow transplant access...
Actinium Pharmaceuticals to Present at the BIO CEO & Investor Conference
February 05, 2018 16:15 ET
|
Actinium Pharmaceuticals
NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it will be attending and presenting at the BIO CEO...